Original Article: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (SOLO1) #ESMO18
We already knew all invasive epithelial ovarian pts should be tested for BRCA1/2. This makes it imperative that it be done at diagnosis. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
This is the most impressive data I've seen yet at #ESMO18. HR=0.30 for PFS and HR=0.5 for PFS2 even with 35% of pts getting PARP 2L. OS not mature, but have to assume it's going to favor olaparib (PFS2 is OS surrogate) $AZN $MRK $CLVS $TSRO
Primary PARP maintenance after upfront treatment for adv #OvarianCancer in BRCA1/2 carriers showed tremendous (~3yrs) improvement in PFS; #ESMO18
Results from the SOLO-1 trial published suggest the use of maintenance therapy w/ Olaparib significantly prolongs PFS vs placebo (after 3 years 60% vs 27%) in newly diagnosed advanced #ovariancancer and a BRCA1/2 mutation.
$AZN $MRK Lynparza in 1L Maintenance BRCAm ovarian cancer data out in NEJM --> $CLVS $TSRO PFS HR=0.30 One of the most amazing PFS curve this year!
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (olaparib tablets 300mg BD) #ovca #gyncsm
For BRCA mutant ovarian cancer. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
The use of maintenance therapy with olaparib provides a substantial benefit in PFS in newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Two years of maintenance therapy with Lynparza, marketed by $AZN and $MRK, reduced the risk of progression in advanced BRCA-positive ovarian cancer by 70%.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM